Sangamo, which recently completed a Phase II ALS clinical trial (http://www.prnewswire.com/news-releases/sangamo-biosciences-announces-presentation-of-phase-2-data-in-amyotrophic-lateral-sclerosis-als-at-society-for-neuroscience-meeting-108756234.html), is striding ahead, applying its zinc-finger technology to combat several other diseases. This article reports on Sangamo’s successful gene therapy approach to treat HIV, in which zinc-finger technology was used to delete the receptor gene necessary for HIV viral entry into lymphocytes. These modified HIV-resistant cells were then infused back into the patients’ bloodsteam. The technology has broad applications for autologous cell based therapies, such as those currently being explored for ALS (link to BrainStorm entry in drug database) and other diseases.
Click here to read more.Share this: